Paul Hutson
Overview
Explore the profile of Paul Hutson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garg S, Chewning B, Hutson P, Astor B, Bartels C
Arthritis Care Res (Hoboken)
. 2023 Sep;
76(2):241-250.
PMID: 37667434
Objective: Recent data show that lower hydroxychloroquine (HCQ) doses are associated with a two- to six-fold higher risk of lupus flares. Thus, establishing an effective reference range of HCQ blood...
2.
Hingorani P, Krailo M, Buxton A, Hutson P, Sondel P, Diccianni M, et al.
Eur J Cancer
. 2022 Jul;
172:264-275.
PMID: 35809374
Purpose: Novel effective therapies are urgently needed in recurrent osteosarcoma. GD2 is expressed in human osteosarcoma tumours and cell lines. This study evaluated the disease control rate (DCR) in patients...
3.
Hutson P, Guieu R, Deharo J, Michelet P, Brignole M, Vander Ark C, et al.
Drugs R D
. 2022 Feb;
22(1):61-70.
PMID: 35150431
Background: Vasovagal syncope is a common cause of syncope which, if recurrent, can have multiple negative consequences such as injury and occupational disability. Various medications can be used to decrease...
4.
Stauffer M, Hutson P, Kaufman A, Morrison A
Drugs R D
. 2017 Oct;
17(4):645-653.
PMID: 29076037
Introduction: Patient adherence to a medication regimen is usually expressed as an adherence rate, defined as the proportion of prescribed doses actually taken. An adherence rate threshold, above which the...
5.
Federico S, McCarville M, Shulkin B, Sondel P, Hank J, Hutson P, et al.
Clin Cancer Res
. 2017 Sep;
23(21):6441-6449.
PMID: 28939747
Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial investigated a fixed dose of a unique anti-GD2 mAb, hu14.18K322A, combined with chemotherapy, cytokines,...
6.
Hutson P, Backonja M, Knurr H
Pain Med
. 2014 Dec;
16(3):531-6.
PMID: 25530475
Objectives: This study was designed to describe the efficacy and toxicity of intravenous (i.v.) lidocaine infusions for the treatment of neuropathic pain initially administered at a flat-rate trial dose of...
7.
Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, et al.
Cancer Chemother Pharmacol
. 2014 Aug;
74(4):875-82.
PMID: 25168296
Purpose: Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy...
8.
Navid F, Sondel P, Barfield R, Shulkin B, Kaufman R, Allay J, et al.
J Clin Oncol
. 2014 Apr;
32(14):1445-52.
PMID: 24711551
Purpose: The addition of immunotherapy, including a combination of anti-GD2 monoclonal antibody (mAb), ch14.18, and cytokines, improves outcome for patients with high-risk neuroblastoma. However, this therapy is limited by ch14.18-related...
9.
Zhang Y, Jiang H, Hutson P
Int J Pharm Compd
. 2012 Oct;
16(2):170-3.
PMID: 23050330
A stability-indicating high-performance liquid chromatography-mass spectrometry times 2 method was developed to establish the stability of acetyl-l-carnitine dissolved in 5% dextrose in water; quantitation of acetyl-l-carnitine and its hydrolysis product...
10.
Zhang Y, Scarlett C, Hutson P
Int J Pharm Compd
. 2012 Oct;
16(1):82-5.
PMID: 23050317
The compatibility of acetyl-l-carnitine with three chemotherapy agents was studied during simulated Y-site administration. Acetyl-l-carnitine 30 mg/mL in 5% dextrose for injection (D5W) was combined with carboplatin 4 mg/mL, paclitaxel...